STANDARD BIOTLS (LAB)
(Delayed Data from NSDQ)
$1.80 USD
+0.25 (16.13%)
Updated Aug 15, 2024 03:59 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LAB 1.80 +0.25(16.13%)
Will LAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LAB
Standard BioTools (LAB) Reports Q2 Loss, Misses Revenue Estimates
5 Medical Info Systems Stock to Buy for a Stable Portfolio
LAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LAB
$1.7M Bet On Standard BioTools? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying
Standard BioTools to Participate in Upcoming Investor Conferences
MercadoLibre Posts Upbeat Results, Joins Integral Ad Science, Willdan Group, Fresh Del Monte Produce And Other Big Stocks Moving Higher On Friday
Maintaining a Buy Rating for Standard BioTools: Overcoming Short-Term Challenges with Long-Term Growth Potential
What You Missed On Wall Street This Morning